{
    "root": "f9273709-b8c3-42fb-85ff-d6c40d449a6e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "UBRELVY",
    "value": "20250321",
    "ingredients": [
        {
            "name": "UBROGEPANT",
            "code": "AD0O8X2QJR"
        },
        {
            "name": "VITAMIN E POLYETHYLENE GLYCOL SUCCINATE",
            "code": "O03S90U1F2"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B"
        }
    ],
    "indications": "UBRELVY is indicated for the acute treatment of migraine with or without aura in adults.\n                  \n                     Limitations of Use \n                  \n                  UBRELVY is not indicated for the preventive treatment of migraine.",
    "contraindications": "The recommended dose is 50 mg or 100 mg taken orally, as needed. ( 2.1 ) If needed, a second dose may be administered at least 2 hours after the initial dose. ( 2.1 ) The maximum dose in a 24-hour period is 200 mg. ( 2.1 ) Severe Hepatic or Severe Renal Impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose. ( 2.2 , 8.6 , 8.7 )",
    "warningsAndPrecautions": "UBRELVY 50 mg is supplied as white to off-white, capsule-shaped, biconvex tablets debossed with “U50” on one side in unit-dose packets (each packet contains 1 tablet):\n                        \n                           Box of 10 Packets, NDC: 0023-6498-10\n                           \n                           Box of 16 Packets, NDC: 0023-6498-16\n                           \n                           Box of 30 Packets, NDC: 0023-6498-30\n                        \n                        UBRELVY 100 mg is supplied as white to off-white capsule-shaped, biconvex tablets debossed with “U100” on one side in unit-dose packets (each packet contains 1 tablet): \n                        \n                           Box of 10 Packets, NDC: 0023-6501-10\n                           \n                           Box of 16 Packets, NDC: 0023-6501-16\n                           \n                           Box of 30 Packets, NDC: 0023-6501-30",
    "adverseReactions": "UBRELVY is contraindicated:\n                  \n                     With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions (\n                        \n                           7.1\n                        \n                        )]\n                        \n                     \n                     In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. Reactions have included anaphylaxis, dyspnea, and facial or throat edema [see Warnings and Precautions (\n                        \n                           5.1\n                        \n                        )]"
}